PHILADELPHIA, Oct. 22 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), the market leader in Attention Deficit Hyperactivity Disorder (ADHD), announced today that it will present key scientific data on its ADHD treatments at a major scientific and educational meeting of child and adolescent psychiatrists to be held October 23-28 in Boston.
"The Shire studies to be presented are indicative of our continuous efforts to provide a diverse range of innovative ADHD treatments," said Eliseo Salinas, M.D., Chief Scientific Officer for Shire. "We are proud to be sharing our new scientific data with the medical community, which include results of the first VYVANSE(TM) study in adults with ADHD and findings from a 12-month study on DAYTRANA(TM), the first and only patch for ADHD approved by the U.S. Food and Drug Administration."
A summary of the key scientific presentations is provided below. Information about the data presentations mentioned in this release is embargoed until the respective presentation sessions have taken place at the meeting.
VYVANSE (lisdexamfetamine dimesylate):
October 25, 2007; 11:00 a.m. EDT
Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults with ADHD
Poster# B34
October 26, 2007; 3:30 p.m. EDT
Lisdexamfetamine Dimesylate Effect Size in Children with ADHD
Poster# E58
DAYTRANA (methylphenidate transdermal system):
October 25, 2007; 11:00 a.m. EDT
Long-Term (Up to 12 months) Use of Methylphenidate Transdermal System
Poster# B60
About ADHD
Approximately 7.8 percent of all school-age children, or about 4.4
million U.S. children aged 4 to 17 years, have been diagnosed with ADHD at
some point in their lives, according to the CDC. ADHD is one of the most
common psychiatric disorders in children and adolescents. The disorder is
also estimated to affect approximately 9.2 million adults across the U.S.
based on a retrospective su
'/>"/>
| SOURCE Shire plc Copyright©2007 PR Newswire. All rights reserved |